First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study.
about
Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patientsG-CSF and GM-CSF in NeutropeniaHematopoietic growth factors: personalization of risks and benefitsDesign Rationale and Development Approach for Pegfilgrastim as a Long-Acting Granulocyte Colony-Stimulating FactorThe impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trialsG-CSF in Peg-IFN induced neutropenia in liver transplanted patients with HCV recurrenceThe effectiveness and safety of same-day versus next-day administration of long-acting granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced neutropenia: a systematic reviewChemotherapy-associated treatment burden in breast cancer patients receiving lipegfilgrastim or pegfilgrastim: secondary efficacy data from a phase III study.Predicting neutropenia risk in patients with cancer using electronic data.A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trialRisk and consequences of chemotherapy-induced neutropenic complications in patients receiving daily filgrastim: the importance of duration of prophylaxis.The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma.Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?Management of neutropenia in cancer patients.Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysisA randomized, double-blind, active control, multicenter, dose-finding study of lipegfilgrastim (XM22) in breast cancer patients receiving myelosuppressive therapy.Effectiveness of daily versus non-daily granulocyte colony-stimulating factors in patients with solid tumours undergoing chemotherapy: a multivariate analysis of data from current practice.Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases.Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications.Overview of supportive care in patients receiving chemotherapy: antiemetics, pain management, anemia, and neutropenia.Therapeutic strategies for chemotherapy-induced neutropenia in patients with solid tumors.Safety and tolerability of docetaxel, cyclophosphamide, and trastuzumab compared to standard trastuzumab-based chemotherapy regimens for early-stage human epidermal growth factor receptor 2-positive breast cancerRisk assessment model for first-cycle chemotherapy-induced neutropenia in patients with solid tumoursEfficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapyUptake of novel medical therapies in the general population.Clinical practice in febrile neutropenia risk assessment and granulocyte colony-stimulating factor primary prophylaxis of febrile neutropenia in Poland.Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy.Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review.Refining docetaxel-containing therapy for gastric cancer.Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapy.The impact of chemotherapy dose intensity and supportive care on the risk of febrile neutropenia in patients with early stage breast cancer: a prospective cohort studyComparative analysis of the efficacy and safety of modified FOLFOX-6 and DCF regimens as first-line treatment in advanced gastric cancer.Prediction of docetaxel monotherapy-induced neutropenia based on the monocyte percentage.Dose response of pegfilgrastim in Japanese breast cancer patients receiving six cycles of docetaxel, doxorubicin, and cyclophosphamide therapy: a randomized controlled trial.Assessing patients' risk of febrile neutropenia: is there a correlation between physician-assessed risk and model-predicted risk?A way forward on the medically appropriate use of white cell growth factorsTrends in neutropenia-related inpatient events.Chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy.Use and delivery of granulocyte colony-stimulating factor in breast cancer patients receiving neoadjuvant or adjuvant chemotherapy-single-centre experiencePegfilgrastim: evidence in support of its use with cytotoxic chemotherapy.
P2860
Q24198118-2E2DD550-BF0E-4D8F-9ECF-B0EB10E01DF5Q26800954-4B66B616-72DD-43B1-8A18-1514A54DF8C2Q26866922-284A778D-5A4E-4F8A-BA7E-4130518BEE3BQ27004054-BFFD27F8-7E28-4548-BD1E-A15BB35FD6DFQ27008080-4F86D244-103B-40AC-971E-C6B31D6371E6Q27490405-D7582CAF-BAA5-4163-ACE7-09A48E0984D4Q29994513-E912FECC-99DC-41DC-B80A-9EB071CD5C00Q30975418-64C58D0D-1BBC-451A-83F4-374BFF84B4C3Q31131362-AB6FA70E-46CE-49A4-93D8-6FE51269EADBQ33350688-5310101C-C1D6-4315-B8CA-FBB13F99A65BQ33602351-F373807C-8FA4-460E-AEB7-51B81629CD5EQ33752272-2BF4E20F-59AA-4BE1-A13D-297E418FC8D9Q33756369-B78EBB2E-4C9C-42F2-8CF7-628253766113Q33762775-530605FF-EB20-405F-91BA-8702087D80B1Q34029496-860098B5-7676-4893-ABA0-75AE5C7F92B7Q34333814-A345D9BB-3BC4-4284-B218-70626A5C86C8Q34553998-413706E3-5050-4784-827C-C44DAD38398AQ34585066-4D9808E9-07F9-43B6-AB33-8E0A5A28CCA0Q34620664-3C4E119F-EA47-4C9C-965F-1AC308FD5CC7Q34635638-9B531289-C359-489D-AC31-A310ECA6E433Q34670717-40DBE992-9EE4-42C1-8A43-3FCDF8873483Q34779671-A234FEBC-6702-4FFA-B0EC-B0FBB8F8D45FQ34858123-0B5FEA7E-50D9-47F0-9049-308A03457FA9Q34941030-3824F428-AE49-41DA-84E4-56D8CF07809EQ35026985-71DA9C70-8767-4613-A21F-5E8E19186894Q35165571-40E0C9F1-9F36-4E40-A43B-1CBE6CD256A8Q35237134-4B08838F-AD5A-4F33-97BB-6101C29596AEQ35303471-97D8E561-CE54-494B-A667-490284235940Q35445166-303D75C5-E22A-4C2A-A60D-321677F3BDC6Q35811836-1642B225-AB7E-4F5E-A231-70A85FDB2C03Q35916166-EE9CB9CC-7A14-4060-800A-DFF6B68ED0CEQ35948108-0324DC20-26E3-4FBC-8D64-D98739C59054Q35995548-CE7BD598-82F8-4D6F-B4AA-63B717CCFFD0Q36004954-E38C6D4C-44BE-403B-81C5-AEF1D04C6AFBQ36023851-A45EF3BD-8838-4A92-9B5E-1B7798CCC8B5Q36058245-FBF33838-CA42-4A05-8218-D034FEF579D1Q36095153-298430CC-8766-41AA-9D66-8F92FC4B924AQ36106810-EB165CDA-CE12-4B85-B504-B2B7AF35CDBCQ36136876-698BF404-C846-4ACE-99F7-5CDEEC2219C6Q36235531-38EBF29E-5998-4F06-8992-859D02008B27
P2860
First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study.
description
2005 nî lūn-bûn
@nan
2005 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
First and subsequent cycle use ...... bo-controlled phase III study.
@ast
First and subsequent cycle use ...... bo-controlled phase III study.
@en
First and subsequent cycle use ...... bo-controlled phase III study.
@nl
type
label
First and subsequent cycle use ...... bo-controlled phase III study.
@ast
First and subsequent cycle use ...... bo-controlled phase III study.
@en
First and subsequent cycle use ...... bo-controlled phase III study.
@nl
prefLabel
First and subsequent cycle use ...... bo-controlled phase III study.
@ast
First and subsequent cycle use ...... bo-controlled phase III study.
@en
First and subsequent cycle use ...... bo-controlled phase III study.
@nl
P2093
P921
P356
P1476
First and subsequent cycle use ...... ebo-controlled phase III study
@en
P2093
Brian L Wiens
Charles L Vogel
Lee S Schwartzberg
Luis Javier Barajas-Figueroa
Robert R Carroll
Sergei A Tjulandin
Theresa A Neumann
P304
P356
10.1200/JCO.2005.09.102
P407
P577
2005-02-01T00:00:00Z